编辑推荐——射频消融与大隐静脉高位结扎剥脱术治疗大隐静脉功能不全的短期成本效果
基于随机对照试验的经济学分析,纳入143例(156条肢体)大隐静脉功能不全患者,比较射频消融(RFA)、高位结扎剥脱术(HL/S)与不治疗或保守治疗的成本效果。随访1年,RFA组每条肢体成本低于HL/S组,每获得一个QALY的成本亦低于HL/S组,两种方法每QALY成本均低于瑞典国家卫生与福利委员会建议的阈值。
要点
- RFA组每例患者成本为1292欧元,HL/S组为2303欧元。
- RFA组QALY增益为0.21,HL/S组为0.17。
- 与不治疗或保守治疗相比,RFA每QALY成本为6155欧元,HL/S为13549欧元。
核心结论
- 在1年随访中,RFA比HL/S以及不治疗或保守治疗更具成本效果。
研究设计与样本
- 基于正在进行的随机对照试验的经济学分析,纳入143例(156条肢体)大隐静脉功能不全(CEAP临床分级2-6级)患者,分别接受RFA或HL/S治疗,随访至1年。
主要发现
- RFA组有78条肢体,HL/S组有78条肢体。
- RFA组中,1条肢体在1个月时大隐静脉存在反流,3条肢体在1年时存在反流。
- HL/S组中,2条肢体在1个月和1年时治疗区域存在残余反流。
- 疾病严重程度(r-VCSS,p = .004)和生活质量(AVVQ,p = .021;EQ-5D-3L,p = .028)随时间显著改善。
- RFA组QALY增益为0.21,HL/S组为0.17;每例患者成本RFA组为1292欧元,HL/S组为2303欧元。
关键数值与推荐
- 不治疗或保守治疗被假定为治疗成本为零且无治疗获益。
- RFA和HL/S两种方法的每QALY成本均远低于瑞典国家卫生与福利委员会建议的阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Superficial venous incompetence (SVI) is a common disease that causes significant quality of life (QoL) impairment. There is a need for more health economic evaluations of SVI treatment. The aim of this study was to perform a cost effectiveness analysis in patients with great saphenous vein (GSV) incompetence comparing radiofrequency ablation (RFA), high ligation and stripping (HL/S), and no treatment or conservative treatment with one year follow up. METHODS: Randomised controlled trial economic analysis from an ongoing trial; 143 patients (156 limbs) with GSV incompetence (CEAP clinical class 2 - 6) were included. Treatment was performed with RFA or HL/S. Follow up was performed up to one year using duplex ultrasound, revised venous clinical severity score (r-VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and EuroQol-5D-3L (EQ-5D-3L). RESULTS: Seventy-eight limbs were treated with RFA and HL/S respectively. No treatment or conservative treatment was assumed to have zero in treatment cost and no treatment benefit. In the RFA group, one limb had reflux in the GSV after one month and three limbs after one year. In HL/S, two limbs had remaining reflux in the treated area at one month and one year. Both disease severity (r-VCSS, p = .004) and QoL (AVVQ, p = .021 and EQ-5D-3L, p = .028) were significantly improved over time. The QALY gain was 0.21 for RFA and 0.17 for HL/S. The cost per patient was calculated as €1 292 for RFA and €2 303 for HL/S. The cost per QALY (compared with no treatment or conservative treatment) was €6 155 for RFA and €13 549 for HL/S. With added cost for days absent from work the cost per QALY was €7 358 for RFA and €24 197 for HL/S. The cost per QALY for both methods was well below the threshold suggested by Swedish National Board of Health. CONCLUSION: RFA is more cost effective than HL/S and no treatment or conservative treatment at one year follow up.
引用
- Nelzén O, Skoog J, Bernfort L, et al. Editor's Choice - Short Term Cost Effectiveness of Radiofrequency Ablation and High Ligation and Stripping for Great Saphenous Vein Incompetence. Eur J Vasc Endovasc Surg. 2024. PMID: 38311050. doi:10.1016/j.ejvs.2024.01.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。